RBC Capital Upgrades Pharmacyclics (PCYC) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Dow leads Wall Street higher, investors focus on healthcare stocks
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 23 | New: 28
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 23 | New: 28
Join SI Premium – FREE
RBC Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Sector Perform to Outperform, price target raised from $15 to $34.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rapport Therapeutics (RAPP) PT Raised to $70 at Guggenheim
- Royal Gold (RGLD) PT Raised to $336 at Raymond James
- Strategy (MSTR) PT Raised to $211 at Clear Street
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
